GCP
IHE icon

GSA Capital Partners’s iShares US Pharmaceuticals ETF IHE Stock Holding History

GSA Capital Partners’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,547
Closed -$216K – 1928
2025
Q4 		$216K Sell
2,547
-1,593
-38% -$127K 0.02% 1363
2025
Q3 		$300K Buy
+4,140
New +$286K 0.03% 1197
2025
Q2 		– Sell
-3,101
Closed -$219K – 1929
2025
Q1 		$219K Sell
3,101
-1,460
-32% -$101K 0.02% 1354
2024
Q4 		$300K Buy
4,561
+1,515
+50% +$104K 0.02% 1203
2024
Q3 		$215K Sell
3,046
-1,225
-29% -$85.4K 0.02% 1394
2024
Q2 		$283K Sell
4,271
-7,425
-63% -$487K 0.02% 1303
2024
Q1 		$794K Buy
11,696
+4,649
+66% +$307K 0.06% 602
2023
Q4 		$436K Buy
7,047
+2,490
+55% +$146K 0.04% 886
2023
Q3 		$269K Buy
4,557
+435
+11% +$26.7K 0.02% 1140
2023
Q2 		$246K Buy
+4,122
New +$245K 0.02% 1158
2022
Q1 		– Sell
-3,552
Closed -$236K – 1590
2021
Q4 		$236K Buy
3,552
+186
+6% +$11.8K 0.03% 1108
2021
Q3 		$205K Buy
+3,366
New +$214K 0.02% 1225

Other funds holding IHE

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
FIA
Foundations Investment Advisors Phoenix, Arizona $9.72B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $14.6B AUM 22.78% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
IWS
Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

GSA Capital Partners's IHE Position: Q1 2026 in Review

GSA Capital Partners sold out of iShares US Pharmaceuticals ETF (IHE) in Q1 2026, closing a stake of 2,547 shares — an estimated $216K sold.

GSA Capital Partners first reported a position in IHE in Q3 2021 and held it in 12 quarters. The position peaked at $794K in Q1 2024. 194 funds tracked by Wall St. Rank hold IHE as of Q1 2026.

  • GSA Capital Partners reported no remaining iShares US Pharmaceuticals ETF position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 2,547 iShares US Pharmaceuticals ETF shares in Q1 2026, an estimated $216K.
  • GSA Capital Partners first reported a position in iShares US Pharmaceuticals ETF in Q3 2021 and held it in 12 quarters.
  • GSA Capital Partners's iShares US Pharmaceuticals ETF position peaked at $794K in Q1 2024.
  • 194 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.